Literature DB >> 8297903

Tumor-bearing animals contain suppressed antitumor effectors the function of which can be unmasked by IL-2.

S Salvadori1, F M Rosenthal, K Cronin, B Gansbacher, K S Zier.   

Abstract

CMS5 fibrosarcoma cells were infected with retroviral constructs containing interleukin-2 (IL-2) cDNA and selected in G418. Parental tumor cells and those that produced IL-2 were injected in vivo. Whereas injection of parental tumor cells resulted in progressive tumor growth, those secreting high levels of IL-2 were rejected. Furthermore, the immunosuppression associated with inoculation of parental tumor cells was not seen. To understand the failure of mice to reject non-IL-2-secreting tumor cells, functional responses of spleen cells from immune and tumor-bearing mice were studied in vitro. As expected, immune spleen cells proliferated under a variety of conditions but were inhibited in the presence of parental tumor cells. Even spleen cells from tumor-bearing animals responded well in the absence of parental tumor cells or in the presence of parental tumor cells, if supplied with adequate levels of IL-2. These results suggest that both tumor-bearing and immune mice generate antitumor effectors but that the cells might be functionally suppressed because of their inability to secrete IL-2 after contact with parental tumor cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8297903     DOI: 10.1097/00002371-199310000-00008

Source DB:  PubMed          Journal:  J Immunother Emphasis Tumor Immunol        ISSN: 1067-5582


  2 in total

1.  Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2.

Authors:  X Cao; W Zhang; S Gu; Y Yu; Q Tao; T Ye
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

2.  Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2.

Authors:  F De Paola; R Ridolfi; A Riccobon; E Flamini; F Barzanti; A M Granato; G L Mordenti; L Medri; P Vitali; D Amadori
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.